Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil versus rituximab versus chlorambucil + rituximab in MALT lymphoma
ISRCTN11144129Phase 3Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2003
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of chlorambucil and rituximab in extranodal marginal zone B-cell lymphoma (EMZL) (3 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Event-free survival. Started Aug 2003; status: completed.
02
Drugs
chlorambucilrituximab
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on ISRCTN11144129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11144129.